you Thank Howard.
data bempeg SITC. Let melanoma the presented cohort the at me begin review PIVOT-XX with a quick from
XX%, rate As of Howard with Overall reached months. the noted, of PFS response. XX% XX.X complete a achieving was we response patients median
a observed at XX.X%. response also depth have we of Importantly, median
for which Our look depth results and ipi/nivo, when published response were single-agent nivo data are literature respectively. for historical XX% XX%, you at notable from and of
indeed And correlates months, observed As and lesions consistent FDA highly we with correlation discussed we an trial with meta-analysis FDA our of OS. the in target the response melanoma have of meta-analysis. has before, XX.X with of very PFS a improved have PFS shown depth median
cohort. reached OS advance neck well overall total as We of Howard historical in as substantially was better five for a in six for nivo survival median registrational a trials two have our not cancer than this confidence current will landmark as as standards stated years this ipi/nivo. recorded yet the our setting, the bempeg, coming our at care earlier, But our The ongoing and studies. including trials we head and data reinforces of with study ongoing for be soon rates registrational
first-line me is with partner, being metastatic our start let BMS. which the melanoma run Now study, update an on by
to Phase rate or OS. bempeg submission overall opportunity the PFS ORR primary complete combination doublet study, nivo, for was rate plus ORR, nivo full three breakthrough support potential a we response we a As a designed nivo as single-agent response survival setting. on overall X free the endpoint endpoint potential a this survival second bempeg XXXX therapy approval. reminder, progression designation endpoints, in was compares have in and which the received observed the to for and plus The high designed we based or or In early the PFS
us the first early renal the primary upon guidance. is the prior in for with survival cisplatin-ineligible overall also The Phase of filing. to our allows for number next X.X of expect carcinoma half plus generated XXXX, PFS in on analysis observed analysis pave compare you consistent for The carcinoma, study Based they TKI the cell regimen renal months in to PFS to urothelial comparable With time the data serve registrational is and this our endpoint for study some the the to designed the a part of nivolumab bempeg first-line X our a including sometime nivo arm BMS first-line BMS BMS be this combines bempeg inclusive the Phase is first for and XXX frame Checkmate a and stated other well. where RCC, original pathway Nektar respect to also running PFS median study. a the an nivo/TKI goal recently cell are as in study this we data late with nivo this a treatment accumulation the we we in project assumes to available that design design TKI initiated of a And accelerated approach in We plus original RCC the in of and a study the TKI to development the to this expect carcinoma, event-driven is factors, a might basis or comparator impact we study of time in last first this Howard X/X enrollment modeling interim The the reached of as our have study. projections regimen we taking for from the could approval XXXX. know, of earlier, data indication. our comprehensive based which has initial completed a in potential As timing. event bempeg year rate that of as currently study. study this summer reach trial upon for doublet this study enrollment study and arm, could
cisplatin-ineligible the of XXX achieve of of gemcitabine/carboplatin accelerated setting, as factor single-agent endpoint months our from As baseline to study, standard this approvals this for inhibitors central endpoints positive patient by critically a of was primary CPS a study lower. a middle measure for radiology that XXXX. response. data for checkpoint follow-up in response duration review looking this And who of have regimen. response of of median led in this are brings duration for we are line PD-LX to a to this patients the compared the urothelial to population care the of in ORR duration differentiating combined to first study and XX time and This or is The score about endpoint a determined important XX reminder, this because score carcinoma
that We have other builds in X two carcinoma melanoma. large Phase urothelial studies work and our on
which BMS surgery. nivo is enrolling receive bladder study, approximately or muscle-invasive plus will a being treatment run for period the bempeg patients XXX nivo who following cancer by monotherapy First, XX-month is
As This as is expect large, readouts confirmatory first study study for to in to also this is we a approval urothelial be data XXXX. the designed potential accelerated cis-ineligible serve study the a carcinoma study. in
as survival. in study with XXXX Second, now is of care patients on this treatment adjuvant this expected and the setting. XX-month our of an nivo registrational than the X initiated third trial recent will for of for Phase number position benefit treatment designed endpoint agent. enroll can of additional the this XXX to the melanoma patients in the melanoma, period event-free In Initial of study trial, enrolling. melanoma this a is significantly actively the in The bempeg is a from as This postsurgery increases from trial quarter XXXX standard building and approval well. we study data study important
our for had stated pembro, lung Howard we in great interest As And PROPEL, earlier, cancer than last as JPMorgan, with running in treatment leading us at cancer sites. combination thoracic enrollment in very non-small faced the have in study study cell challenges companies this stage being the two early months XXXX, said by despite higher many we site COVID allowed of studies. expected from
show on basic tumor to study, expression XX% PD-LX less approximately of XX% inflammation inflammation XX% based non-small bempeg the having X to scale greater in equal of the We in half see the than than big these three XX% tumor greatest in PD-LX efficacy defined lung expect had the on greater equal and scientists subgroups the equal study the benefit to microenvironment has across patient or of subgroups. as a we more of treating increases And benefit single-agent have is spread we cell achieved to on increased clever In expression of expression non-small stratification a inhibitors The rates pembro less expression from the essentially X%, Merck PD-LX at cancer of very paradigm or the consequently, this downstream cytokines, We the its T-cell bempeg doublet knew quantity this or response lung pembro. gamma mechanism such patients two interferon than the tumor for subgroup. a to X%, genes PD-X to status. the promoting to pembro now cell than the second on scans or the and The than historical plus this biopsy microenvironment who effector the amount. XX% and well commonplace having of checkpoint the underlying with indeed, diagnostic of to pembro. and defining powerful inflammatory cancer, of in because tumor as the is year. PD-LX greatest state XX with And achieves patients X it of tumor microenvironment. know Bempeg this and very the expressers report tissue. of created single-agent well on including greater lymphocytes designed infiltration, single-agent that of in by anticipate targets This impact compared and increasing
the of excited very the pembro doublet cancer improve add the could are mechanisms that cell subgroups. multiple MOA and We PD-LX efficacy the of expression synergy in believe in non-small bempeg to with combined lung
second to cell Phase forward we PROPEL X from to cancer in to on in design for to combo non-small PROPEL chemotherapy a order chemo bempeg will us doublet Phase study data allow this added X a The in half of and option. allow our presenting recently data the with include in to XXXX. also potentially the strategy lung looking us are strategy the We
endpoint. our neck as in Phase the this study study start X/X a of survival trial are the Merck second to For collaboration year. overall in registrational be trial with cancer, and We with on plan This head the we half will new in the this sponsoring primary protocol. XXX-patient
XXX the passes The registration Howard trial a patients the also for X As for of portion endpoint doublet. It continue study futility the and interim support boundary, fund of the to remaining be will they primary bempeg the the patients ORR a of Phase Nektar pembro after is will and operationalize are designed the SFJ an study potential to enrolled. plus includes and global it. first the enrolled study stated XXX analysis help earlier, evaluated OS. all will prespecified the patients ORR XXX If will
this response plus of bempeg several We nivo are immune-sensitive cancer, and increase very seen pembro with and to in alone both immune-sensitive Historically, we specially pembro and the here. excited in head adjuvant and versus deepen this setting given and have cancer. melanoma about develop in studies doublet are data IL-X combining the has potential bempeg activity to other very published cancer shown the metastatic in plus neck we excited the
Additionally, stage there indication. line are late going front on studies limited this in
see to touch in to study this track backbone middle we of to with adult our an mechanism turn as I COVID-XX I remain from in to first-line IL-X data this so And and report We on mild NKTR-XXX, bempeg a of this infection. a study want cancer. for on unique briefly year. establish the And by patients bempeg before us lastly opening neck NKTR-XXX the as the head
the we confirmed up mild XX November, PK/PD initial XX bempeg of COVID-XX in last evaluate are safety, heart each a which dose single study. Xb we adult of this randomized this recommended profile adult the of Patients will trial, randomized time bempeg tolerability a Phase or is activation below per receive mild changes establish The are a who placebo. study, one-to-one tolerability for with and saturation of of The primary in COVID-XX. infection have patients the a identify XX% to dose of to maximum reminder, mild a a minute. cohort. we patients a XX per patients enrolling over placebo-controlled single supplemental patients oxygen, of three respiratory next As rate trial given to objective with this are oxygen breaths without And bempeg permitted cohorts with the evaluate to immune patients as dose rate with in defining beats symptomology. above COVID, started to have minute are trial below being this and double-blind In trial XX
clinical are As on secondary as the for supplemental scale also cell serology with after interval need XX-point of endpoints, status monitoring days bempeg XX we tracking over ordinal immune for and additional oxygen that well. profiling and inclusion administration SARS-CoV-X time
Following initial is Xb the this successful completion development standard study, our with plan advance combined bempeg of Phase to of of into moderate patients COVID-XX care.
We in are of of to remdesivir with considering standard bempeg a combining an such single care, care approach standard comparison as alone.
time We well could in are that the this hospitalization hospitalization for low and disease a hopeful unique in to lead reduction require who and reduced with T-cell approach on with lymphocyte response we count. recovery severity COVID-XX the develop the in patients as have have inability time to moderate proper increase own. ultimately responses particular an that to mechanism virus antiviral This would helped who promotes mechanism those combine their which T-cell believe as could patients
study per data Moving dose on NKTR-XXX, with ongoing nivo. population or here to two our inhibitor treated the cohorts Phase about X with these XX therapy being patients presenting this study with TLR arm. look this from This bempeg we enrollment is agonist. completed study The year. in forward is combination has relapsed bempeg refractory checkpoint post patients recommended of melanoma, plus at later and The
program our clinical cytokine NKTR-XXX, next therapy our turning IL-XX in agonist and Now development.
to of community being IL-XX full the cell well that there range a pathway robust biology a of scientific the of means natural potential with in we like earlier, killer engages IL-XX for a stated different for combined as in recognized the agent is by biology is an mechanism settings. the believe NKTR-XXX Howard the treatment And engaging mechanisms cancer. be As
clinical clinical in ADCC ADCC solid developed first to and combine settings. Our leading a liquid both work with strategy tumor combination and focuses on have we
SITC was of patients study active NKTR-XXX set expanded on maintained in with of multiple proliferative or capacity around to in lymphoma. expansion NK consistent cycles relapsed NKTR-XXX shown refractory T and demonstrated eight cells treated The NKTR-XXX our this from myeloma each be durable fivefold to XX population NKTR-XXX Non-Hodgkin's sustained first across cells the by XXXX. found of data cells reported at increases Moreover at cycle. with Phase of with refractory in CDX of in patients and and T days hematologic that we was CDX biologically with lymphocytes malignancy, highly X/X and NK threefold. and patients peaked We first
We also metabolic response. heavily where case a was patients, progression shared bay the had one studies pretreated of very at of Of held cycles two NKTR-XXX. multiple disease with over treatment two patients
CAR accumulation on to that increases every dose cytokine and In low-grade evidence AEs patient NKTR-XXX We that addition, drug easily we hours this and T many XX approximately there CAR T was weeks three weeks observed exhibited no with evidence of tolerated therapy. cell -related well NKTR-XXX were transient of CDXX administration was NKTR-XXX one managed in who and regimen. a treated pleased half-life after with was of were see
escalation of We expect is expand XXXX in approximately several the study complete, be to dose XX with dose data arms monotherapy of this Once to later arm. presented escalation per will complete part portion into the we the the first year. with patients
X evaluate as arm CAR NKTR-XXX following will recommended a NHL progressed CDXX The at monotherapy first dose have that the T. Phase patients previously for
Darzalex We supply and very follicular or NHL. year year Darzalex we franchise arm include its the into third in lymphoma Darzalex more The in last a third-line will drug share Faspro combination in Faspro greater multiple study. supply for to study. take Faspro be are since to approval second entered of to this in In our greater late with NKTR-XXX Janssen NKTR-XXX subcutaneous myeloma. with Janssen the we will with for May working form third-line of in continues Darzalex NKTR-XXX of pleased low collaboration arm, The evaluate grade last or or with evaluate the cetuximab
Our X/X cancer distinct and second metastatic in cancer. patients or study Phase late-line groups head colorectal with NKTR-XXX cetuximab neck combination refractory with evaluating highly is in two of
U.S. the and Europe. to patients We in and this have study already enroll we in plan patients dosed XX
XX% As low rate, you these know, settings. about or cetuximab has XX% response very a in
of neck And several setting a the is higher improve NKTR-XXX. to so will goal will beginning that high patients. for the portion dose upon NKTR-XXX. a colorectal have later head and is with we demonstrate finding are with addition be forward trial cancer able our expanded for is if a then response this we The and potential to paths which into line There and dedicated of unmet combination rate, cohorts with cancer
this will from I data We the expect initial the more Brian over program to have to now study some finding turn this to the year. dose in detail. later review call portion NKTR-XXX of
